← Leaderboards
George C Prendergast
Lankenau Institute For Medical Research
$9,759,368
Attributed
$10,628,358
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,628,358 · 8
By mechanism
R01$10,067,167 · 6
R21$401,141 · 1
R03$160,050 · 1
Top collaborators
- Melvin Reichman3 shared
- Iraimoudi S Ayene1 shared
Most similar at Lankenau Institute For Medical Research
Same institution · by research overlap
- Vincent J. Cristofalo$1,445,025
- Melvin Reichman$1,342,323
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellCellsMalignant NeoplasmsBaseInnovationGeneticSmall MoleculeEnzymesLaboratory MouseNeoplasm /Cancer GeneticsLeadPathway InteractionsPharmaceutical PreparationsCytotoxic ChemotherapyTumorInhibitor/AntagonistMediatingImmuneInflammatoryResponsePre-ClinicalProgramsCancer PatientApoptosis
Grant awards (38)
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$515,870
R01 · FY2024 · DK · contact PI
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$540,254
R01 · FY2023 · DK · contact PI
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$599,356
R01 · FY2022 · DK · contact PI
IDO2 Targeting in Pancreatic Cancer$379,675
R01 · FY2019 · CA · contact PI
IDO2 Targeting in Pancreatic Cancer$391,418
R01 · FY2018 · CA · contact PI
IDO2 Targeting in Pancreatic Cancer$391,418
R01 · FY2017 · CA · contact PI
IDO2 Targeting in Pancreatic Cancer$391,418
R01 · FY2016 · CA · contact PI
IDO2 Targeting in Pancreatic Cancer$407,668
R01 · FY2015 · CA · contact PI
IDO inhibitors for combinatorial cancer therapy$239,997
R01 · FY2015 · CA · contact PI
IDO inhibitors for combinatorial cancer therapy$232,882
R01 · FY2014 · CA · contact PI
IDO inhibitors for combinatorial cancer therapy$229,510
R01 · FY2013 · CA · contact PI
OPPC targeting to improve pancreatic cancer treatment$77,550
R03 · FY2013 · CA · contact PI
IDO inhibitors for combinatorial cancer therapy$244,249
R01 · FY2012 · CA · contact PI
IDO2 Targeting for pancreatic cancer treatment$174,446
R21 · FY2012 · CA · contact PI
OPPC targeting to improve pancreatic cancer treatment$82,500
R03 · FY2012 · CA · contact PI
IDO inhibitors for combinatorial cancer therapy$260,594
R01 · FY2011 · CA · contact PI
IDO2 Targeting for pancreatic cancer treatment$226,695
R21 · FY2011 · CA · contact PI
Role of RHO in Farnesyltransferase Inhibitor Responses$307,211
R01 · FY2008 · CA · contact PI
RhoB Signaling in Cancer Suppression and Cell Suicide$316,456
R01 · FY2007 · CA · contact PI
Role of RHO in Farnesyltransferase Inhibitor Responses$307,211
R01 · FY2007 · CA · contact PI
IDO Inhibitors for Combinatorial Cancer Therapy$267,180
R01 · FY2007 · CA · contact PI
RhoB Signaling in Cancer Suppression and Cell Suicide$325,907
R01 · FY2006 · CA · contact PI
Role of RHO in Farnesyltransferase Inhibitor Responses$316,386
R01 · FY2006 · CA · contact PI
IDO Inhibitors for Combinatorial Cancer Therapy$275,160
R01 · FY2006 · CA · contact PI
Regulation of the MAP Kinase Pathway in Senescence$352,102
R01 · FY2005 · AG
RhoB Signaling in Cancer Suppression and Cell Suicide$333,750
R01 · FY2005 · CA
Role of RHO in Farnesyltransferase Inhibitor Responses$324,000
R01 · FY2005 · CA
IDO Inhibitors for Combinatorial Cancer Therapy$293,736
R01 · FY2005 · CA
RhoB Signaling in Cancer Suppression and Cell Suicide$30,088
R01 · FY2005 · CA
RhoB Signaling in Cancer Suppression and Cell Suicide$333,750
R01 · FY2004 · CA
Role of RHO in Farnesyltransferase Inhibitor Responses$324,000
R01 · FY2004 · CA
RhoB Signaling in Cancer Suppression and Cell Suicide$328,370
R01 · FY2003 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$224,177
R01 · FY2003 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$207,932
R01 · FY2002 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$29,515
R01 · FY2002 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$100,898
R01 · FY2001 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$74,865
R01 · FY2001 · CA
ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSES$170,164
R01 · FY2000 · CA